Trials / Not Yet Recruiting
Not Yet RecruitingNCT06444789
AI-PROGNOSIS - Digital Biomarkers Development Study (dBM-DEV)
AI-based Parkinson's Disease Risk Assessment and Prognosis - Digital Biomarkers Development, Validation and Verification Study (AI-PROGNOSIS dBM-DEV Study)
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 90 (estimated)
- Sponsor
- University Hospital, Toulouse · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
dBM-dev study is a multicentre low-intervention research study which concerns REM sleep behaviour disorder (RBD) who is the best predictor for neurodegenerative diseases including Parkinson's disease (PD). RBD can only be confirmed by polysomnography, which is a cumbersome procedure. The main objective of this study is to identify a novel, robust dBM for the detection of RBD using smartwatch-based recordings of passive data.The study is conducted step-wise on two subsequent cohorts referred to as the development cohort and the confirmation cohort.
Detailed description
The development cohort comprises 30 patients with RBD and 30 matched controls on sex and age with patients RBD. The confirmation cohort comprises 30 patients with PD. Following a baseline visit comprising standard clinical evaluation and Parkinson questionnaires, participants will undergo daily-life dBM tracking over a duration of 4 weeks for development cohort and 3 months for confirmation cohort. Additionally, PD patients enrolled in the confirmation cohort will receive a polysomnography which permits to verificate if they have a RBD. The investigation is conducted in four European sites.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | connected smartwatch | The smartwatch is worn by the patient and data are sent automatically to a server that detects if there are signs of RBD. |
Timeline
- Start date
- 2024-09-20
- Primary completion
- 2025-07-15
- Completion
- 2025-07-15
- First posted
- 2024-06-06
- Last updated
- 2024-08-27
Locations
4 sites across 4 countries: France, Germany, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT06444789. Inclusion in this directory is not an endorsement.